From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes
<b>Background:</b> Type 1 diabetes (T1D) is a severe chronic T-cell mediated autoimmune disease that attacks the insulin-producing beta cells of the pancreas. The multifactorial nature of T1D involves both genetic and environmental components, with recent research focusing on the gut mic...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/15/2/138 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850080640449380352 |
|---|---|
| author | Lente Blok Nordin Hanssen Max Nieuwdorp Elena Rampanelli |
| author_facet | Lente Blok Nordin Hanssen Max Nieuwdorp Elena Rampanelli |
| author_sort | Lente Blok |
| collection | DOAJ |
| description | <b>Background:</b> Type 1 diabetes (T1D) is a severe chronic T-cell mediated autoimmune disease that attacks the insulin-producing beta cells of the pancreas. The multifactorial nature of T1D involves both genetic and environmental components, with recent research focusing on the gut microbiome as a crucial environmental factor in T1D pathogenesis. The gut microbiome and its metabolites play an important role in modulating immunity and autoimmunity. In recent years, studies have revealed significant alterations in the taxonomic and functional composition of the gut microbiome associated with the development of islet autoimmunity and T1D. These changes include reduced production of short-chain fatty acids, altered bile acid and tryptophan metabolism, and increased intestinal permeability with consequent perturbations of host (auto)immune responses. <b>Methods/Results:</b> In this review, we summarize and discuss recent observational, mechanistic and etiological studies investigating the gut microbiome in T1D and elucidating the intricate role of gut microbes in T1D pathogenesis. Moreover, we highlight the recent advances in intervention studies targeting the microbiota for the prevention or treatment of human T1D. <b>Conclusions:</b> A deeper understanding of the evolution of the gut microbiome before and after T1D onset and of the microbial signals conditioning host immunity may provide us with essential insights for exploiting the microbiome as a prognostic and therapeutic tool. |
| format | Article |
| id | doaj-art-edfee8edf0ad433a9a007717e274b4e5 |
| institution | DOAJ |
| issn | 2218-1989 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj-art-edfee8edf0ad433a9a007717e274b4e52025-08-20T02:44:53ZengMDPI AGMetabolites2218-19892025-02-0115213810.3390/metabo15020138From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 DiabetesLente Blok0Nordin Hanssen1Max Nieuwdorp2Elena Rampanelli3Department of Internal and Vascular Medicine, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, The NetherlandsDepartment of Internal and Vascular Medicine, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, The NetherlandsDepartment of Internal and Vascular Medicine, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, The NetherlandsDepartment of Internal and Vascular Medicine, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, The Netherlands<b>Background:</b> Type 1 diabetes (T1D) is a severe chronic T-cell mediated autoimmune disease that attacks the insulin-producing beta cells of the pancreas. The multifactorial nature of T1D involves both genetic and environmental components, with recent research focusing on the gut microbiome as a crucial environmental factor in T1D pathogenesis. The gut microbiome and its metabolites play an important role in modulating immunity and autoimmunity. In recent years, studies have revealed significant alterations in the taxonomic and functional composition of the gut microbiome associated with the development of islet autoimmunity and T1D. These changes include reduced production of short-chain fatty acids, altered bile acid and tryptophan metabolism, and increased intestinal permeability with consequent perturbations of host (auto)immune responses. <b>Methods/Results:</b> In this review, we summarize and discuss recent observational, mechanistic and etiological studies investigating the gut microbiome in T1D and elucidating the intricate role of gut microbes in T1D pathogenesis. Moreover, we highlight the recent advances in intervention studies targeting the microbiota for the prevention or treatment of human T1D. <b>Conclusions:</b> A deeper understanding of the evolution of the gut microbiome before and after T1D onset and of the microbial signals conditioning host immunity may provide us with essential insights for exploiting the microbiome as a prognostic and therapeutic tool.https://www.mdpi.com/2218-1989/15/2/138type 1 diabetesgut microbiomemetabolitesshort-chain fatty acidsbeta cell function |
| spellingShingle | Lente Blok Nordin Hanssen Max Nieuwdorp Elena Rampanelli From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes Metabolites type 1 diabetes gut microbiome metabolites short-chain fatty acids beta cell function |
| title | From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes |
| title_full | From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes |
| title_fullStr | From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes |
| title_full_unstemmed | From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes |
| title_short | From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes |
| title_sort | from microbes to metabolites advances in gut microbiome research in type 1 diabetes |
| topic | type 1 diabetes gut microbiome metabolites short-chain fatty acids beta cell function |
| url | https://www.mdpi.com/2218-1989/15/2/138 |
| work_keys_str_mv | AT lenteblok frommicrobestometabolitesadvancesingutmicrobiomeresearchintype1diabetes AT nordinhanssen frommicrobestometabolitesadvancesingutmicrobiomeresearchintype1diabetes AT maxnieuwdorp frommicrobestometabolitesadvancesingutmicrobiomeresearchintype1diabetes AT elenarampanelli frommicrobestometabolitesadvancesingutmicrobiomeresearchintype1diabetes |